Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals by Schwalbe, Oliver et al.
RESEARCH ARTICLE Open Access
Compliance assessment of ambulatory Alzheimer
patients to aid therapeutic decisions by
healthcare professionals
Oliver Schwalbe
1,2†, Christian Scheerans
1,2†, Ines Freiberg
1, Andrea Schmidt-Pokrzywniak
3, Andreas Stang
3,
Charlotte Kloft
1,2*†
Abstract
Background: Compliance represents a major determinant for the effectiveness of pharmacotherapy. Compliance
reports summarising electronically compiled compliance data qualify healthcare needs and can be utilised as part
of a compliance enhancing intervention. Nevertheless, evidence-based information on a sufficient level of
compliance is scarce complicating the interpretation of compliance reports. The purpose of our pilot study was to
determine the compliance of ambulatory Alzheimer patients to antidementia drugs under routine therapeutic use
using electronic monitoring. In addition, the forgiveness of donepezil (i.e. its ability to sustain adequate
pharmacological response despite suboptimal compliance) was characterised and evidence-based guidance for the
interpretation of compliance reports was intended to be developed.
Methods: We determined the compliance of four different antidementia drugs by electronic monitoring in 31
patients over six months. All patients were recruited from the gerontopsychiatric clinic of a university hospital as
part of a pilot study. The so called medication event monitoring system (MEMS) was employed, consisting of a vial
with a microprocessor in the lid which records the time (date, hour, minute) of every opening. Daily compliance
served as primary outcome measure, defined as percentage of days with correctly administered doses of
medication. In addition, pharmacokinetics and pharmacodynamics of donepezil were simulated to systematically
assess therapeutic undersupply also incorporating study compliance patterns. Statistical analyses were performed
with SPSS and Microsoft Excel.
Results: Median daily compliance was 94% (range 48%-99%). Ten patients (32%) were non-compliant at least for
one month. One-sixth of patients taking donepezil displayed periods of therapeutic undersupply. For 10 mg and 5
mg donepezil once-daily dosing, the estimated forgiveness of donepezil was 80% and 90% daily compliance or
two and one dosage omissions at steady state, respectively. Based on the simulation findings we developed rules
for the evidence-based interpretation of donepezil compliance reports.
Conclusions: Compliance in ambulatory Alzheimer patients was for the first time assessed under routine
conditions using electronic monitoring: On average compliance was relatively high but variable between patients.
The approach of pharmacokinetic/pharmacodynamic in silico simulations was suitable to characterise the
forgiveness of donepezil suggesting evidence-based recommendations for the interpretation of compliance reports.
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Alzheimer’s disease presents the most common type of
dementia, accounting for 50%-60% of all cases [1]. In
2001, more than 24 million people worldwide were suf-
fering from dementia, a number that is expected to dou-
ble every 20 years up to 81 million in 2040 due to
increase in life expectancy [1]. Cholinesterase inhibitors
such as donepezil, galantamine and rivastigmine and the
NMDA-receptor modulator memantine present the
first-line pharmacotherapy for Alzheimer’sd i s e a s e[ 2 , 3 ] .
Prescription data from a large statutory health insurance
in Germany show that donepezil and memantine are the
market leaders, each representing approximately one
third of all defined daily doses of all four agents [4].
T h e s ea g e n t sc a ni m p r o v es ymptoms, primarily in the
domains of cognition (e.g. ADAS-cog score) and global
function [5]. Effectiveness should be evaluated in two to
four months intervals [6].
Within outcomes research compliance presents a
treatment modifier, which highly impacts the effective-
ness of pharmacotherapy [7]. Studies investigating com-
pliance show a variety of measures of medication usage
and varying terminologies (e.g. compliance, adherence,
persistence) complicating the interpretation and com-
parison of those studies [8,9]. The Medication Compli-
ance and Persistence Work Group of the International
Society of Pharmacoeconomics and Outcomes Research
(ISPOR) defined medication compliance as “the extent
to which a patient acts in accordance with the pre-
scribed interval and dose of a dosing regimen”[8]. Per-
sistence may be referred to as “the duration of time
from initiation to discontinuation”. Today, no overarch-
ing term combines these two concepts [8].
Since the end of the 1970s electronic monitoring has
been used to compile dose administration histories of
ambulatory patients [10]. The so called medication
event monitoring system (MEMS) consists of a vial with
a microprocessor in the lid which records the time
(date, hour, minute) of every opening [11]. In contrast
to traditional compliance assessment methods such as
pill count, patient diaries or patient self-report, the
method of electronic monitoring demonstrated to be a
more reliable tool allowing a detailed analysis of patient
medication taking behaviour over time [12]. However, as
indirect method actual ingestion of the medicine cannot
be measured [10] and compliance may be underesti-
mated (e.g. in the case that a weekly pill-box is used
instead) [13]. In addition, MEMS in itself presents a
compliance enhancing intervention for patients who are
informed about the purpose of the device. This may
lead to an overestimation of their “usual” medication
taking behaviour. Nevertheless, electronic monitoring
has been recognised closest to a ‘gold standard’ for
compliance measurement [11]. To our knowledge, com-
pliance studies among Alzheimer patients using electro-
nic monitoring have not been conducted until now.
Previous studies have employed pharmacy refill data to
investigate medication taking behaviour [14-17]. Reports
summarising MEMS data characterise compliance-time
patterns in detail and can be utilised as part of a com-
pliance enhancing intervention where a healthcare pro-
fessional provides feedback to the patient on his/her
medication taking behaviour [18]. This was termed mea-
surement-guided medication management (MGMM).
The advent of electronic monitoring has also advanced
research on the question “how much compliance is
enough?” being closely related to the concept of forgive-
ness. Urquhart defined forgiveness as the “drug’sp o s t -
dose duration of action minus the prescribed interval
between doses” [10]. Researchers in the HIV area have
adopted a more general definition of forgiveness as abil-
ity of a regimen to achieve and sustain adequate phar-
macological response (in this case viral suppression)
despite suboptimal compliance [19]. In the present work
forgiveness is used in the latter sense, specifying the for-
mer as forgiveness according to Urquhart. The crucial
‘experiment’ for measuring how much compliance is
sufficient, presents the controlled, blinded substitution
of placebos for active drug [20]. This is frequently not
ethically possible and has only been pursued in the field
of e.g. oral contraception, hypertension and depression
[20,21]. Furthermore, a correlation between compliance
and clinical outcome was established in observational
studies [22,23].
The capacity for forgiveness of drugs may differ sub-
stantially, depending on their pharmacokinetic (PK, i.e.
the drug exposition) and pharmacodynamic (PD, i.e. the
drug effect) properties, e.g. clearance and steepness of
concentration-effect relationship. Thus, given a known
pharmacokinetic/pharmacodynamic (PK/PD) relation-
ship, in silico studies were also suggested for the charac-
terisation of forgiveness [24,25]. In the case of
donepezil, the degree of inhibition of peripheral choli-
nesterase has been identified as a PD biomarker [26]. In
this work we defined “time with therapeutic undersup-
ply” (TTU) as a parameter. To avoid TTU, the daily
dosages of cholinesterase inhibitors to achieve a consis-
tent red blood cell (RBC) cholinesterase inhibition of at
least 40% corresponded to those causing improvements
in ADAS-cog and functional activity scores [27].
The aim of our pilot study was to determine the com-
pliance of ambulatory Alzheimer patients to antidemen-
tia drugs under routine therapeutic use by means of
electronic monitoring over a six months period. In addi-
tion, we performed pharmacokinetic/pharmacodynamic
in silico simulations using the pilot study compliance
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ise the forgiveness of donepezil, the most frequently pre-
scribed antidementia drug. Ultimately, we aimed at
developing a recommendation for the evidence-based
interpretation of donepezil compliance reports which
may form the basis of a MGMM intervention.
Methods
Study design
The current research was part of a sequential phase II
trial (pilot study) within the Medical Research Council
framework [28] (guidance for the development and eva-
luation of complex interventions) investigating the
impact of a pharmaceutical care intervention on ambu-
latory Alzheimer patients’ compliance and other out-
comes such as knowledge in pharmacotherapy and
caregivers’ health-related quality of life. Our pharmaceu-
tical care program in the second part of the trial should
include a complex intervention including MGMM. The
study was approved by the respective ethics committee
(Ethics Board 4) of the Charité - Universitaetsmedizin
Berlin, Germany. Patients had to fulfil the following
inclusion criteria: diagnosis of Alzheimer’s disease; pre-
scription of an antidementia drug (ATC-code N06D);
living in ambulatory setting; sufficient command of the
German language (patient and caregiver); ability to con-
sent (patient). Patients who lived in residential homes or
who intended to move further away during the study
period were not eligible according to study protocol.
Patients were consecutively recruited from the above
mentioned clinic. The study design comprised a one
month run-in phase followed by a main phase lasting
six months. All study individuals screened between
March 2006 and July 2007 were Alzheimer patients
of the gerontopsychiatric clinic of the Charité -
Universitaetsmedizin Berlin, Germany. The recruited
patients were a convenience sample and comprised the
standard care group of the phase II trial.
Standard care denoted community pharmacists pro-
vided their usual dispensing service that included appro-
priate drug information and advice for patients
according to the Ordinance on the Operation of Phar-
macies [29]. No defined compliance enhancing interven-
tion to the patient or caregiver was offered. Having
obtained written informed consent from patients and
caregivers, the antidementia drug was repacked into a
MEMS container. Patients and caregivers were informed
about the monitoring device. Each patient/caregiver was
given the instruction to open the MEMS container
when they wanted to take a medicine, to remove and
take the prescribed dose, then promptly close the device.
Additionally, patients’ regular community pharmacy was
informed and trained how to perform and document
the repackaging procedure.
Compliance
Compliance was determined using MEMS 6 TrackCap
(Aardex Ltd., Zug, Switzerland). Refills of MEMS vials
were performed and documented in patients’ regular
community pharmacies. Subsequently, refill events and
self-reported non-usage periods (e.g. due to hospital
stays) were removed from the dataset. Daily compliance
in the main phase served as primary outcome measure,
defined as percentage of days with the correct number
of MEMS openings (e.g. two openings for a twice daily
drug) acting on the usual assumption that opening cor-
responded to drug intake. Daily compliance was calcu-
lated for each individual month as well as the total main
phase comprising six months. Additionally patients were
dichotomised into ‘compliers’ (daily compliance ≥ 80%
according to the commonly employed cut-off criterion)
and ‘non-compliers’ (daily compliance < 80%) [30]. For
descriptive data analysis of MEMS recordings of our
study, means or medians were calculated as measure of
central tendency. According to the attributes of the
respective variables, we calculated range, quartiles and
95% confidence interval. In contrast to the large amount
of MEMS data the sample size of patients was small. In
this part, no statistical test or extrapolations were per-
formed based on individual data. Statistical analyses
were performed with SPSS 15 (SPSS Inc., Chicago, Ill,
USA).
Forgiveness
To characterise the forgiveness of donepezil, PK/PD in
silico simulations were performed using Microsoft Excel
2003 (Microsoft Corp., Redmond, WA, USA). Three
approaches (A, B and C) were applied via trace-driven
simulations [31] using different compliance patterns as
input (function): Approach A used the compliance data
from the pilot study to evaluate therapeutic undersupply
for all individual patients taking donepezil. Approaches
B and C served as sensitivity analyses to characterise the
forgiveness of donepezil. For approach B, discrete daily
compliance values (0%-100%) were simulated using a
step size of 10%. These selected compliance patterns
were created by the pseudo-random number generator
in Microsoft Excel, for a period of 200 days. Eventually
for approach C, scenarios of 1-7 dosage omissions at
steady-state after a 14 days run-in phase and with a
7 days follow-up phase were simulated. The utilised PK
and PD models are summarised in Table 1.
For donepezil, linear PK was assumed [27].The plasma
concentration-time course of donepezil for long-term
treatment with (irregular) multiple dosing (up to 200
days with Δt = 1 min) was generated using a previously
published PK model [32], applying the principle of
superposition, as explained in [33]. In case of approach
C where dosage omissions at steady state conditions
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next dose administered was accordingly extended, e.g.
doubled (48 h instead of 24 h) for one missing dose.
The resulting plasma concentration-time course of
donepezil (for multiple dosing) was directly linked to
the PD model (see Table 1) describing the inhibition of
peripheral cholinesterase that served as PD biomarker
[34]. The main outcome variable for all three simula-
tions was the “time with therapeutic undersupply”
(TTU). TTU was defined as time (percentage or hour)
with the PD biomarker below the minimum therapeutic
inhibition, that is < 40% inhibition of peripheral choli-
nesterase. Additionally, for approach C forgiveness
according to Urquhart was determined as the “drug’s
post-dose duration of action minus the prescribed inter-
val between doses” [10].
Results
Compliance
From 39 patients who fulfilled the inclusion criteria 31
(79%) were enrolled into the study. The main reason (6
out of 8 refusals) for nonparticipation was MEMS-
related inconveniences (e.g. incompatibility of MEMS
and use of weekly pill-boxes).
Fifty percent of all patients were between 71 and 82
years old and both sexes were almost equally repre-
sented. Duration of antidementia pharmacotherapy at
inclusion ranged from drug-naïve to 6.5 years with 2-12
concomitantly administered drugs. The majority
of patients were on a once daily antidementia regimen
with donepezil being the most prevailing drug. More-
over, in more than two-thirds of all patients the
caregiver only was responsible for pharmacotherapy
(Table 2). In total, 6507 MEMS openings were recorded
over 5399 days.
Median compliance of all patients in the main phase
was 94% with a large range of 48% to 99% (lower quar-
tile: 87%, upper quartile: 98%). In comparison to the
first month, median compliance decreased by 7% points
in the sixth month (Fig. 1).
After dichotomisation of compliance (daily compliance
80% and more or < 80%), intraindividual compliance
patterns by month revealed that 10 patients (32%, 95%
confidence interval: 17%-51%) were at least one month
non-compliant (Fig. 2). Among these, two patients were
non-compliant throughout the main phase.
Forgiveness of donepezil
To determine their possible therapeutic undersupply
individual compliance patterns of the twelve patients of
the study comprising 1873 MEMS recordings with either
5 mg (n = 3) or 10 mg (n = 9) once daily donepezil were
simulated (approach A). In the 5 mg donepezil dosing
group, two patients (#13 and #23) out of three were
undersupplied during certain time periods. Moreover, for
both patients it was found that one occasionally omitted
Table 1 Pharmacokinetic and pharmacodynamic models for donepezil
Model type (name) & equation Variables and parameters Reference
Pharmacokinetic model
(two compartment model)
CD
Ae
Be
ABe
tl a g t i m e
t lagtime
kt l a g t i m a
=⋅
⋅+
⋅
+⋅
−−
−− −
−⋅ −


()
()
( ()
e e)
⎡
⎣
⎢
⎢
⎢
⎢
⎤
⎦
⎥
⎥
⎥
⎥
for D = 5 mg:
A = 3.502 ng/mL
B = 1.209 ng/mL
a = 0.445 h
-1
b = 0.014 h
ka = 1.319 h
-1
lag time = 0.96 h
for D = 10 mg:
A = 4.536 ng/mL
B = 1.234 ng/mL
a = 0.542 h
-1
b = 0.015 h
-1
ka = 1.696 h
-1
lag time = 0.68 h
[32]
Pharmacodynamic model
(Emax model)
Emax = 100.8%
EC50 = 15.6 ng/mL
[34]
E
EC
EC C =
⋅
+
max
50
Parameter values and reference to literature, utilised for the in silico simulation.
C = total plasma drug concentration [ng/mL]
t = time [h]
D=d o s e
A, B = intercepts of the two exponential terms
a, b = macro (hybrid) rate constants
ka = absorption rate constant
E = effect, i.e. inhibition of peripheral cholinesterase, %
Emax = maximum effect
EC50 = drug concentration at half of maximum effect
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undersupply. However, series of one dose omission trig-
gered the appearance of undersupplied periods. Very
interestingly, daily compliance in the main phase for
patient #13 and #23 was 87.2% and 80.0%, respectively,
i.e. they were regarded as compliant according to the
commonly employed 80% cut-off criterion. None of the
patients taking 10 mg donepezil displayed any undersup-
plied periods.
Simulations of discrete compliance values are dis-
played in Fig. 3 (approach B). For 10 mg (5 mg) donepe-
zil negligible therapeutic undersupply was observed with
daily compliance exceeding 80% (90%) leading to 0.3%
(2.9%) TTU of total time. Fig. 3 revealed a sigmoidal
relationship between TTU and discrete compliance
values. For efficacious pharmacotherapy, however, TTU
of total time should be negligible, i.e. close to zero.
Approach C characterised the influence of 1-7 dosage
omissions on the inhibition of cholinesterase (Fig. 4):
Initially, both curves ran parallel to the abscissa. Subse-
quently, TTU linearly increased with a higher number
of dosage omissions with comparable slope. In the case
of 5 mg donepezil two or more dosage omissions caused
therapeutic undersupply. For 10 mg three or more
dosage omissions at steady state led to therapeutic
undersupply. Forgiveness according to Urquhart was
calculated as 68.4 h for 10 mg and 28.3 h for 5 mg
donepezil, respectively, i.e. the PD effect lasted for
almost 3 d and more than 1 d beyond the dosing inter-
val, respectively.
Evidence-based interpretation of compliance reports for
donepezil
Based on our results, for 5 mg donepezil, a monthly
daily compliance less than 90% or two consecutive
dosage omissions were regarded as therapeutically rele-
vant non-compliance. For 10 mg donepezil we regarded
a monthly daily compliance of less than 80% or three
consecutive dosage omissions as a trigger of therapeuti-
cally relevant non-compliance.
Discussion
In this study, we provide evidence from non-invasively
acquired data that compliance of ambulatory Alzheimer
patients in their daily life seems to be relatively high
with on average one non-compliant day out of ten.
Nevertheless, about one third of all patients were at
least one out of six months non-compliant employing
t h ef r e q u e n t l yu s e d8 0 %c u t - o f fc r i t e r i o n .P K / P D
in silico simulations revealed that for 10 mg (5 mg)
donepezil forgiveness of donepezil was estimated as 80%
Table 2 Characteristics of the patients at baseline (n = 31)
and study characteristics
Characteristics
n (%)
Sex: women 17 (55)
Responsibility for pharmacotherapy
Patient only 2 (6)
Patient supported by caregiver 6 (19)
Caregiver only 22 (71)
Professional care only 1 (3)
Antidementia drugs in MEMS
a
Donepezil 12 (39)
Galantamine 12 (39)
Memantine 7 (23)
Rivastigmine 1 (3)
Regimen of antidementia drug in MEMS
a
Once daily 24 (75)
Twice daily 8 (25)
median
(range)
Age in years 76 (47-96)
Duration of MEMS monitoring in days
b 180 (140-
180)
Duration of antidementia pharmacotherapy at inclusion
in months
18 (0-78)
Number of regularly administered drugs 6 (2-12)
MEMS, medication event monitoring system;
a one patient was started on
donepezil (MEMS monitoring during 49 days), but later in the course of the
study he was switched to memantine (MEMS monitoring during 111 days);
b
eight out of 31 patients (26%) had non-monitored periods (e.g. due to
hospital stays) or incomplete follow-up of less than 180 days.
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Figure 1 Daily compliance during study observation period for
each month and the entire observation period. The ends of the
whiskers represent the lowest data value within 1.5 times the box
height from the lower box edge and the highest data value within
1.5 times the box height from the upper box edge, respectively.
Index numbers represent individual patients ID: if associated with
circle, this ID was regarded as outlier (1.5-3 times box height from
the box edge), if with a star as extreme value (> 3 times box height
from the box edge); mo. = month.
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steady-state, respectively. Based on these results, evi-
dence-based recommendations for the detection of rele-
vant non-compliance were developed to aid the
interpretation of compliance reports as part of e.g. a
MGMM.
Electronic monitoring of medication events - based on
electronic detection of opening a container - presents an
indirect method of estimating when and how much drug
has been taken. Direct measures such as directly
observed therapy and therapeutic drug monitoring may
be feasible in certain areas (e.g. intensive care units) but
not in others, as in our setting and patient population
due to the high effort required. Errors in compliance
estimation will occur if a patient opens the container
without taking the drug or takes another number of
tablets than the one prescribed. In addition, apparently
irrational openings could also be detected in the investi-
gated population (in 61% of all patients, but only in
approximately 1% of all openings). Arnet and Haefeli
recognised so called “curiosity events” in nearly 20% of
patients’ electronic monitoring systems which were due
to showing the device to relatives or friends or uncer-
tainty whether they had closed the electronic monitoring
device [35].
Denhaerynck et al. provided a form to their patients to
document deviations from “normal” usage of the moni-
toring device (e.g. during hospital stays) as well as con-
ducted a structured interview with each patient at the
end of the study [36]: Uncensored data showed a 3.4%
higher non-compliance than the censored data (incor-
porating information of forms and interviews). Hence,
non-censoring could be considered as an overestimation
of non-compliance [36]. Nevertheless, another study
revealed that uncorrected electronic monitoring data
could successfully project measured plasma concentra-
tions of drugs [37]. In our study, pharmacy refills and
self-reported non-usage periods (e.g. due to hospital
stays) were excluded from further analysis which may
relevantly improve the quality of the data.
Denhaerynck et al. investigated the compliance enhan-
cing effect in transplant patients by omitting the first
month of electronic monitoring from their analysis: This
only resulted in a 0.4% decrease in daily compliance.
They concluded that the compliance enhancing effect of
electronic monitoring only had minor clinical signifi-
cance [36]. Nevertheless, the run-in phase of one month
as part of our study design may reduce this effect, thus
giving a more realistic picture of medication taking
behaviour.
Electronic monitoring presents the most reliable
method for the determination of compliance despite
certain disadvantages [11]. Three studies determined
persistence for donepezil and rivastigmine in treatment
naïve patients using pharmacy-refill data [14-17]. Nearly
one third of all patients stopped donepezil or rivastig-
mine therapy within 60 days of starting therapy [15].
There were no marked differences in persistence
between both drugs [15,17]. Especially during the dosage
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Figure 2 Intraindividual daily compliance during the
observation period. Compliant months (daily compliance ≥ 80%,
white bars) or non-compliant months (daily compliance < 80%, grey
bars); patient #11 and patient #31 participated five months only.
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trointestinal) occur that usually cease later in the course
[38]. With the exception of one patient there were no
treatment naïve participants in our study being particu-
larly prone to adverse drug reactions. This patient was
down-titrated to 5 mg donepezil from 10 mg due to
a d v e r s ed r u ge f f e c t sb u td i dn o ts t o pt h e r a p y .I nt h e
study conducted by Roe and co-workers 14% of all
patients who continued therapy for at least 6 months
showed gaps in supply for at least six weeks [16]. In our
study, around one third of all patients were considered
non-compliant (80% cut-off criterion) in at least one
month demonstrating how much more sensitive electro-
nic monitoring has to be regarded compared to phar-
macy refill data. During the course of the study, median
compliance slightly decreased by 7% points. In future, a
longer study should be performed to assess whether the
decrease will be more substantial over a longer period.
Inhibition of peripheral cholinesterase served as a bio-
marker of pharmacological response in Alzheimer’s
disease. Jann et al. concluded that daily doses of cholines-
terase inhibitors to achieve a consistent peripheral choli-
nesterase inhibition of at least 40% corresponded to those
leading to an improvement in cognition and functional
activity scores [27]. Elsewhere, positive associations were
reported between the AChE inhibition and change in
ADAS-cog and CIBIC plus [34]. Unfortunately, the
strength of association was not reported by Rogers et al.
and thus the predictive value of RBC AChE inhibition has
been discussed [34,39] it nevertheless provides evidence of
potential efficacy. Hence, 40% inhibition served as a rea-
sonable cut-off below which only minor efficacy has to be
expected.
Donepezil was chosen for characterising the forgive-
ness in the in silico analysis due to the following rea-
sons: (i) most widely used acetylcholinesterase inhibitor,
(ii) high number of MEMS data available (2720 moni-
tored days), and (iii) an available PK as well as PD
model and an established dose-response relationship.
The PK model included the long half-life of donepezil
of 50 h. Since population pharmacokinetic models that
provide variability parameters are not available, PK varia-
bility could not be employed in the in silico study. More-
over, for approaches B and C, investigating the influence
of daily compliance and dosage omission on therapeutic
coverage/undersupply, a high magnitude of PK variability
c o u l dp r o v i d eam o r es o p h i s t icated picture of the out-
come. Future in silico simulations for donepezil should
account for population PK models that quantify variabil-
ity, when available. In addition, subgroup analysis for
confounders should be performed with a larger data base
considering the metabolising isoenzymes, cytochrome
P450 3A4 and the 2D6 which can be induced or inhibited
by comedication. Besides, the current simulation had to
be limited to donepezil because for other antidementia
drugs literature data was mostly insufficient but highly
warranted. For galantamine, a PK model was available
but no PD model [40]. An exception presented rivastig-
mine as oral capsules where a PK/PD model was
described in the literature [41]. Due to the low number
of rivastigmine data of our study (one patient only), its
low market share (13%) [4] and increasing acceptance of
a transdermal formulation with differing PK/PD charac-
teristics lacking published PK models we did not find it
adequate to perform a simulation.
From three patients being prescribed donepezil who
were at least one month non-compliant (daily compli-
ance < 80%) two displayed periods of therapeutic under-
supply. Especially the combination of a drug holiday
(dosing interval exceeding 96 h) and several single dose
omissions triggered therapeutic undersupply. The long
half-life of donepezil (~50 h) might at first glance exclude
this drug from being interesting for forgiveness analysis.
But as shown in our investigation, forgiveness is in fact
an issue for donepezil in certain non-compliance patterns
(e.g. several dose omissions). These patterns in electronic
monitoring reports present an indicator of potential
insufficient therapeutic coverage and have to be dis-
cussed with the patient/caregiver [18]. In the absence of
electronic monitoring patients or caregivers should be
questioned in an empathic, non-patriarchic style about
their medication taking behaviour. An old, still widely-
held idea going back to research in the cardiovascular
field in the 1960 s, was that taking 80% of the prescribed
doses generally qualifies as satisfactory compliance [42].
This view, however, has to be regarded as pharmacodyna-
mically naïve since forgiveness of each drug product is
determined by its individual dosage form, PK and PD
[43]. Our results reveal that 80% compliance already
results in more than 10% therapeutic undersupply for
5 mg donepezil daily whereas 10 mg daily maintains
almost full therapeutic coverage, i.e. for 5 mg donepezil
we now suggest 90% compliance to serve as a cut-off.
Both donepezil dosages forgive a common compliance
error: one occasionally omitted tablet. Compared to
other therapeutic areas donepezil exhibited a high
degree of forgiveness. If a single gestagen-only pill is
taken more than three hours late, there will be a need
of back-up contraception [44]. The forgiveness of once
daily antihypertensives atenolol and betaxolol can be
estimated as about 6 hours and more than 48 hours
[45]. These results were generated by controlled (verum
only group), blinded trials partially substituting verum
against placebo, whereas we have implemented in silico
simulations, in this way providing a lower level of evi-
dence. Studies early in the era of antiretroviral therapy
demonstrated the need for > 95% compliance in order
to achieve and sustain viral suppression [19]. High rates
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erate compliance with newer antiretroviral regimens
(e.g. lopinavir/ritonavir) [23]. Beyond this, sparse or no
evidence is available on forgiveness of major therapeutic
classes.
Conclusions
For the first time, this pilot study assessed compliance
under routine therapeutic use of ambulatory Alzheimer
patients using electronic monitoring. Compliance in
ambulatory Alzheimer patients was relatively high but
variable. The approach of pharmacokinetic/pharmacody-
namic in silico simulations was suitable to characterise
the forgiveness of donepezil giving evidence-based
recommendations for the design of the intervention part
of our study (MGMM-guided complex intervention of
the pharmaceutical care program) and for the interpre-
tation of compliance reports .I n f o r m a t i o no np a t i e n t s ’
compliance (percentage and pattern) should be incorpo-
rated in decisions whether to continue therapy in the
case of therapeutic failure.
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